Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 6, 2023

Advances in Research and Applications of Cardiac Organoids

Download as PDF

DOI: 10.23977/medsc.2023.040612 | Downloads: 5 | Views: 259

Author(s)

Fuwenxuan Ding 1

Affiliation(s)

1 Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, 999077, China

Corresponding Author

Fuwenxuan Ding

ABSTRACT

Cardiovascular disease (CVD) prevalence and mortality have been in an increasing stage globally, which is one of the main causes of death and poses a serious threat to human health. The research related to cardiovascular diseases is mainly based on traditional two-dimensional (2D) cell models and animal models, but due to some limitations, they cannot be fully applied to the research of cardiovascular disease pathogenesis and treatment methods. Organoid technology is a kind of three-dimensional (3D) biological tissue engineering constructed in vitro, which can highly simulate the cellular structure and physiological function of organs in vivo, providing a new direction and idea for the research of cardiovascular diseases. Therefore, cardiac organoid, as an effective complement to traditional cardiovascular disease models, has great potential in the study of disease mechanisms, drug experimentation, regenerative medicine and many other fields. This paper summarizes the construction methods of cardiac organoids and their applications in cardiovascular diseases, and also presents its development prospects, challenges and directions to be improved.

KEYWORDS

Cardiac Organoids, Cardiovascular Disease, Disease Model, Pluripotent Stem Cells, hPSCs

CITE THIS PAPER

Fuwenxuan Ding, Advances in Research and Applications of Cardiac Organoids. MEDS Clinical Medicine (2023) Vol. 4: 76-82. DOI: http://dx.doi.org/10.23977/medsc.2023.040612.

REFERENCES

[1] Mensah, G. A., Roth, G. A., and Fuster, V. (2019) The Global Burden of Cardiovascular Diseases and Risk Factors. Journal of the American College of Cardiology, 74, 2529–2532.
[2] Roth, G. A., Mensah, G. A., Johnson, C. O., and Addolorato, G. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology, 76, 2982–3021.
[3] Writing committee of the report on cardiovascular health and diseases in china. (2022) Report on Cardiovascular Health and Diseases in China 2021: An Updated Summary. Biomedical and environmental sciences: BES, 35, 573–603.
[4] Gorzalczany, S. B., and Rodriguez Basso, A. G. (2021) Strategies to apply 3Rs in preclinical testing. Pharmacology Research & Perspectives, 9, e00863.
[5] Kim, J., Koo, B.-K., and Knoblich, J. A. (2020) Human organoids: model systems for human biology and medicine. Nature Reviews Molecular Cell Biology, 21, 571–584.
[6] Rossi, G., Manfrin, A., and Lutolf, M. P. (2018) Progress and potential in organoid research. Nature Reviews Genetics, 19, 671–687.
[7] Lancaster, M. A., and Knoblich, J. A. (2014) Organogenesis in a dish: Modeling development and disease using organoid technologies. Science, 345, 1247125–1247125.
[8] Clevers, H. (2016) Modeling Development and Disease with Organoids. Cell, 165, 1586–1597.
[9] Schutgens, F., and Clevers, H. (2020) Human Organoids: Tools for Understanding Biology and Treating Diseases. Annual Review of Pathology: Mechanisms of Disease, 15, 211–234.
[10] Xu, H., Jiao, Y., Qin, S., Zhao, W., Chu, Q., and Wu, K. (2018) Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. Experimental Hematology & Oncology, 7, 30.
[11] Hofbauer, P., Jahnel, S. M., Papai, N., Giesshammer, M., Deyett, A., Schmidt, C., et al. (2021) Cardioids reveal self-organizing principles of human cardiogenesis. Cell, 184, 3299–3317.e22.
[12] Chen, V. C., Ye, J., Shukla, P., Hua, G., Chen, D., Lin, Z., et al. (2015) Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. Stem Cell Research, 15, 365–375.
[13] Guyette, J. P., Charest, J. M., Mills, R. W., Jank, B. J., Moser, P. T., Gilpin, S. E., et al. (2016) Bioengineering Human Myocardium on Native Extracellular Matrix. Circulation Research, 118, 56–72.
[14] Cho, J., Lee, H., Rah, W., Chang, H. J., and Yoon, Y. (2022) From engineered heart tissue to cardiac organoid. Theranostics, 12, 2758–2772.
[15] Kupfer, M. E., Lin, W.-H., Ravikumar, V., Qiu, K., Wang, L., Gao, L., et al. (2020) In Situ Expansion, Differentiation, and Electromechanical Coupling of Human Cardiac Muscle in a 3D Bioprinted, Chambered Organoid. Circulation Research, 127, 207–224.
[16] Zhang, Y. S., Arneri, A., Bersini, S., Shin, S.-R., Zhu, K., Goli-Malekabadi, Z., et al. (2016) Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. Biomaterials, 110, 45–59.
[17] Lindsey, M. L., de Castro Brás, L. E., DeLeon-Pennell, K. Y., Frangogiannis, N. G., Halade, G. V., O’Meara, C. C., et al. (2021) Reperfused vs. nonreperfused myocardial infarction: when to use which model. American Journal of Physiology-Heart and Circulatory Physiology, 321, H208–H213.
[18] Richards, D. J., Li, Y., Kerr, C. M., Yao, J., Beeson, G. C., Coyle, R. C., et al. (2020) Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. Nature Biomedical Engineering, 4, 446–462.
[19] Tzatzalos, E., Abilez, O. J., Shukla, P., and Wu, J. C. (2016) Engineered heart tissues and induced pluripotent stem cells: macro- and microstructures for disease modeling, drug screening, and translational studies. Advanced drug delivery reviews, 96, 234–244.
[20] Shinnawi, R., Shaheen, N., Huber, I., Shiti, A., Arbel, G., Gepstein, A., et al. (2019) Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell–Derived Cardiac Cell Sheets. Journal of the American College of Cardiology, 73, 2310–2324.
[21] Zhang, Y., Zhang, J., Butler, J., Yang, X., Xie, P., Guo, D., et al. (2017) Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results from the China Heart Failure (China-HF) Registry. Journal of cardiac failure, 23, 868–875.
[22] Tiburcy, M., Hudson, J. E., Balfanz, P., Schlick, S., Meyer, T., Chang Liao, M.-L., et al. (2017) Defined Engineered Human Myocardium with Advanced Maturation for Applications in Heart Failure Modeling and Repair. Circulation, 135, 1832–1847.
[23] Majumdar, U., Yasuhara, J., and Garg, V. (2019) In Vivo and In Vitro Genetic Models of Congenital Heart Disease. Cold Spring Harbor Perspectives in Biology, 13, a036764.
[24] Nees, S. N., and Chung, W. K. (2019) Genetic Basis of Human Congenital Heart Disease. Cold Spring Harbor Perspectives in Biology, 12, a036749.
[25] Drakhlis, L., Biswanath, S., Farr, C.-M., Lupanow, V., Teske, J., Ritzenhoff, K., et al. (2021) Human heart-forming organoids recapitulate early heart and foregut development. Nature Biotechnology, 39, 737–746.
[26] Mokry, L. E., Ahmad, O., Forgetta, V., Thanassoulis, G., and Richards, J. B. (2014) Mendelian randomisation applied to drug development in cardiovascular disease: a review. Journal of Medical Genetics, 52, 71–79.
[27] Lal-Nag, M., McGee, L., Guha, R., Lengyel, E., Kenny, H. A., and Ferrer, M. (2017) A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discovery, 22, 494–506.
[28] Van de Wetering, M., Francies, Hayley E., Francis, Joshua M., Bounova, G., Iorio, F., Pronk, A., et al. (2015) Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. Cell, 161, 933–945.
[29] Mills, R. J., Parker, B. L., Quaife-Ryan, G. A., Voges, H. K., Needham, E. J., Bornot, A., et al. (2019) Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway. Cell stem cell, 24, 895–907.e6.
[30] Xuan, W., Tipparaju, S. M., and Ashraf, M. (2022) Transformational Applications of Human Cardiac Organoids in Cardiovascular Diseases. Frontiers in Cell and Developmental Biology, 10, 936084.
[31] Sallam, K., Thomas, D., Gaddam, S., Lopez, N. E., Beck, A., Beach, L. Y., et al. (2022) Modeling Effects of Immunosuppressive Drugs on Human Hearts Using Induced Pluripotent Stem Cell–Derived Cardiac Organoids and Single-Cell RNA Sequencing. Circulation, 145, 1367–1369.
[32] Takeda, M., Miyagawa, S., Fukushima, S., Saito, A., Ito, E., Harada, A., et al. (2018) Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells. Tissue Engineering Part C: Methods, 24, 56–67.
[33] Cossu, G., Birchall, M., Brown, T., De Coppi, P., Culme-Seymour, E., Gibbon, S., et al. (2018) Lancet Commission: Stem cells and regenerative medicine. The Lancet, 391, 883–910.
[34] Gao, L., Gregorich, Z. R., Zhu, W., Mattapally, S., Oduk, Y., Lou, X., et al. (2018) Large Cardiac Muscle Patches Engineered From Human Induced-Pluripotent Stem Cell–Derived Cardiac Cells Improve Recovery From Myocardial Infarction in Swine. Circulation, 137, 1712–1730.
[35] Varzideh, F., Pahlavan, S., Ansari, H., Halvaei, M., Kostin, S., Feiz, M.-S., et al. (2019) Human cardiomyocytes undergo enhanced maturation in embryonic stem cell-derived organoid transplants. Biomaterials, 192, 537–550.
[36] Sakaguchi, H., Kadoshima, T., Soen, M., Narii, N., Ishida, Y., Ohgushi, M., et al. (2015) Generation of functional hippocampal neurons from self-organizing human embryonic stem cell-derived dorsomedial telencephalic tissue. Nature Communications, 6, 8896.
[37] Jabs, J., Zickgraf, F. M., Park, J., Wagner, S., Jiang, X., Jechow, K., et al. (2017) Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations. Molecular Systems Biology, 13, 955.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4545
Visits: 196817

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.